Japan’s drug regulatory agency has authorized two new administration methods for Rystiggo (rozanolixizumab) — an approved treatment for generalized myasthenia gravis (gMG) — that people with the chronic autoimmune condition can use at home. These approvals, by the Pharmaceuticals and Medical Devices Agency, or PMDA, will allow gMG…
Enrollment is now complete for a Phase 2 clinical trial testing Dianthus Therapeutics‘ treatment candidate DNTH103 in people with generalized myasthenia gravis (gMG). According to the developer, the initial results from the global study, dubbed MAGIC (NCT06282159), are expected by early fall. MAGIC was launched early…
Levels of antibodies against muscle-specific kinase (MuSK) are not reflective of disease severity in people with MuSK-positive myasthenia gravis (MG), according to a study. “Given our results, MuSK autoantibodies are not suitable as biomarkers for clinical severity or prognosis in MuSK-positive MG,” the researchers wrote. The study, “…
Long-term treatment with nipocalimab led to sustained reductions in symptom severity among antibody-positive patients with generalized myasthenia gravis (gMG) in a Phase 3 clinical trial. That’s according to new data presented by its developer, Johnson & Johnson, at the American Academy of Neurology (AAN) Annual Meeting this…
Treatment with the cell therapy Descartes-08 led to long-term reductions in symptom severity for people with myasthenia gravis (MG) taking part in a Phase 2b clinical trial, according to updated data announced by therapy developer Cartesian Therapeutics. “Participants dosed with a single six-week course of treatment of…
Scientists in Korea have developed a cell-based test that can be used to detect antibodies against agrin, a protein involved in nerve-muscle communication that is sometimes targeted by harmful autoantibodies in people with myasthenia gravis (MG). The researchers said they validated the test “and have demonstrated that this [cell-based…
More than 500 members of the myasthenia gravis (MG) community are expected at a conference featuring strategies for patient education, advances in science and treatment, and discussions on managing MG. The Myasthenia Gravis Foundation of America (MGFA)’s National Patient Conference, being held March 30-April 1 in Phoenix and virtually, is…
One year of treatment with inebilizumab eased symptoms and improved daily functioning for people with generalized myasthenia gravis (gMG) positive for antibodies against the acetylcholine receptor (AChR), according to new data from the Phase 3 MINT clinical trial. Amgen, the company developing inebilizumab, will present the new…
Repeated cycles of Rystiggo (rozanolixizumab-noli) do not increase the risk of safety problems in people with generalized myasthenia gravis (gMG), according to a new analysis of clinical trial data. “These results showed that treatment with [Rystiggo] in patients with gMG was well tolerated and that the incidence of…
Rituximab can safely and effectively control myasthenia gravis (MG) in patients with antibodies against muscle-specific kinase or MuSK, according to a new analysis. “Rituximab has demonstrated effectiveness and safety as a treatment for anti-MuSK MG. It has the potential to help patients with any baseline severity, especially those…
Get regular updates to your inbox.
